Loading...
01/10 16:06
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates improved financial performance with increased revenue and decreased losses. However, cash reserves have decreased, and management avoided specific cash burn guidance, raising concerns. Product commercialization is progressing, but timelines are not immediate. The Q&A highlights potential in large markets, but lacks detailed revenue projections. Overall, the mixed signals and lack of immediate catalysts suggest a neutral sentiment towards short-term stock movement.
Total Revenue $967,000 for the quarter ended June 30, 2025, compared to $386,000 for the same period a year ago, representing a significant increase. The increase was driven by the $250,000 milestone revenue from the Inzymes agreement and grant revenue from the Gates Foundation and CEPI program.
Cost of Research and Development Revenue and Cost of Grant Revenue $614,000 for the quarter ended June 30, 2025, compared to $302,000 for the same period a year ago, showing an increase. This was related to the cost of grant revenue from the Gates Foundation and CEPI.
Research and Development Expenses $629,000 for the quarter ended June 30, 2025, compared to $516,000 for the same period a year ago, reflecting an increase. The rise was driven by a higher number of active internal research initiatives to expedite product development.
General and Administrative (G&A) Expenses $1,437,000 for the quarter ended June 30, 2025, compared to $1,608,000 for the same period a year ago, showing a decrease. The reduction was due to lower business development and investor relation expenses, accounting and legal expenses, insurance expenses, and management incentives.
Loss on Operations $1,729,000 for the quarter ended June 30, 2025, compared to $2,043,000 for the same period a year ago, indicating a decrease. This was due to reductions in operating expenses.
Net Loss $1,794,000 or $0.06 per share for the quarter ended June 30, 2025, compared to $2,045,000 or $0.07 per share for the same period a year ago, showing a decrease. This was attributed to improved revenue and reduced operating expenses.
Cash and Cash Equivalents Approximately $7.3 million as of June 30, 2025, compared to $9.3 million as of December 31, 2024, reflecting a decrease. The reduction was due to operational expenses and investments.
C1 and Dapibus platforms: Precision engineered fungal expression platforms for high-yield animal-free recombinant proteins across life sciences, food nutrition, and bioindustrial applications.
Recombinant human albumin: On track for 2025 launch in partnership with Proliant Health & Biologics, with $1 million milestone payments received and $500,000 expected in Q3.
RNase-Free DNase1: Scaled-up production for biopharmaceutical manufacturing and molecular diagnostics, with sampling and commercial discussions underway.
Alpha-lactalbumin: Developed production strains for food and research markets, with initial revenues expected in 2026.
Human lactoferrin: Exploring partnerships in precision fermentation for food nutrition and research use.
EN3ZYME: Enzyme cocktail for biofuel production, actively sampling with prospective customers.
Life sciences: Targeting cell culture media and molecular biology reagent markets with animal-free solutions for biopharmaceutical manufacturing, gene therapy, and diagnostics.
Food nutrition: Focusing on sustainable, functional, and animal-free proteins for infant formula, medical nutrition, and wellness products.
Bioindustrial: Addressing challenges in industrial biotechnology with enzyme solutions for biofuels, pulp and paper, and biogas industries.
Leadership and operational transformation: Shifted from R&D-focused to market-facing revenue-driven biotechnology business.
Financial strengthening: Completed $5.3 million equity raise to fund product development and launches.
Strategic focus: Prioritizing high-growth nontherapeutic markets with scalable protein production platforms.
Legacy programs: Advancing vaccine and therapeutic R&D through fully-funded collaborations with organizations like the Gates Foundation and CEPI.
Market Conditions: The company is targeting high-demand nontherapeutic markets, but these markets are subject to consumer preferences, regulatory shifts, and supply chain pressures, which could impact the adoption of their products.
Regulatory Hurdles: The company must meet specific performance and regulatory needs for its products in various markets, including life sciences, food nutrition, and bioindustrial sectors. Failure to comply could hinder product launches and market penetration.
Supply Chain Disruptions: The company relies on partnerships and external manufacturing options for scaling up production. Any disruptions in these partnerships or supply chains could delay product launches and revenue generation.
Economic Uncertainties: The company’s financial performance is dependent on achieving milestones and securing additional revenues. Economic downturns or funding challenges could impact their ability to sustain operations and execute strategic priorities.
Strategic Execution Risks: The company is transitioning from an R&D-focused organization to a revenue-driven business. This shift requires effective execution of commercialization strategies, which, if unsuccessful, could impact financial performance and market position.
Competitive Pressures: The company operates in competitive markets such as life sciences, food nutrition, and bioindustrial sectors. Competitors with established products and resources could pose challenges to market entry and growth.
Revenue Growth: The company anticipates achieving its third and last milestone of $500,000 in revenue from Proliant in 2025, along with additional income from DNase1 and other products.
Product Launches: Dyadic plans to launch recombinant human albumin in 2025 in partnership with Proliant Health & Biologics. A first product launch for non-animal dairy enzymes is targeted for late 2025, with additional enzyme candidates progressing under the existing license. Initial revenues from recombinant alpha-lactalbumin are expected in 2026.
Market Expansion: The company is targeting high-growth nontherapeutic markets, including life sciences, food nutrition, and bioindustrial segments, with a focus on sustainable, animal-free protein production.
Financial Position: Dyadic strengthened its financial foundation with a $5.3 million equity raise on August 1, 2025, to fund late-stage product development, scale-up, and multiple upcoming product launches.
Life Sciences Segment: The company is advancing programs for scalable animal-free solutions in cell culture media and molecular biology applications, including recombinant human albumin, transferrin, and fibroblast growth factors (FGFs).
Food Nutrition Segment: Dyadic is developing recombinant alpha-lactalbumin and human lactoferrin for food and research markets, with initial revenues expected in 2026. The company is also exploring partnerships in the precision fermentation segment.
Bioindustrial Segment: The company is focusing on enzyme cocktails for biofuel production, pulp and paper applications, and biogas industry, with revenues anticipated in 2026.
Global DNA and RNA Molecular Biology Reagent Market: Dyadic is targeting this market with RNase-Free DNase1, with sampling in progress and active discussions with potential commercial partners.
The selected topic was not discussed during the call.
The earnings call reveals mixed signals. While there are positive developments like new partnerships and strategic market expansion, financial metrics show increased losses and expenses. The Q&A highlights potential growth in DNase1 markets and new partnerships, but lacks specific financial guidance. Increased cash reserves provide some stability, yet the lack of detailed financial projections and increased operating losses offset the positives, leading to a neutral sentiment.
The earnings call summary indicates improved financial performance with increased revenue and decreased losses. However, cash reserves have decreased, and management avoided specific cash burn guidance, raising concerns. Product commercialization is progressing, but timelines are not immediate. The Q&A highlights potential in large markets, but lacks detailed revenue projections. Overall, the mixed signals and lack of immediate catalysts suggest a neutral sentiment towards short-term stock movement.
The earnings call reveals mixed signals. Positive aspects include revenue growth, decreased R&D expenses, and strategic partnerships. However, financial challenges persist with ongoing net losses and a decrease in cash reserves. The lack of a shareholder return plan and unclear guidance on key partnerships and burn rates further contribute to uncertainty. While there are promising product developments and market opportunities, competition and regulatory hurdles pose risks. The Q&A session highlighted management's evasiveness on some issues, reinforcing a neutral outlook. Given the absence of market cap data, the stock price is likely to remain stable in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
